These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36511267)

  • 21. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
    Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
    Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
    da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
    Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
    Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
    Sankin A; Hakimi AA; Mikkilineni N; Ostrovnaya I; Silk MT; Liang Y; Mano R; Chevinsky M; Motzer RJ; Solomon SB; Cheng EH; Durack JC; Coleman JA; Russo P; Hsieh JJ
    Cancer Med; 2014 Dec; 3(6):1485-92. PubMed ID: 25124064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
    Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
    Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
    Oka S; Inoshita N; Miura Y; Oki R; Miyama Y; Nagamoto S; Ogawa K; Sakaguchi K; Kondoh C; Kurosawa K; Urakami S; Takano T; Okaneya T
    Urol Oncol; 2018 Aug; 36(8):365.e9-365.e14. PubMed ID: 29853346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.
    Kapur P; Christie A; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Xie XJ; Lotan Y; Margulis V; Brugarolas J
    J Urol; 2014 Mar; 191(3):603-10. PubMed ID: 24076305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
    Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
    Mehdi A; Riazalhosseini Y
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
    Singh RR; Murugan P; Patel LR; Voicu H; Yoo SY; Majewski T; Mehrotra M; Wani K; Tannir N; Karam JA; Jonasch E; Wood CG; Creighton CJ; Medeiros LJ; Broaddus RR; Tamboli P; Baggerly KA; Aldape KD; Czerniak B; Luthra R; Sircar K
    Mod Pathol; 2015 Sep; 28(9):1225-35. PubMed ID: 26111976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Milanese G; Di Primio R; Montironi R; Muzzonigro G
    Urol Oncol; 2016 Aug; 34(8):338.e11-8. PubMed ID: 27085487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
    Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
    Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
    Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.